G250 refers to a monoclonal antibody (mAb) that was raised more than 10 years ago by immunization of mice with human renal cell carcinoma(RCC) homogenates. The RCC-associated transmembrane protein designated G250 has since been proven to be identical to tumor-associated protein MN or CA IX. The normal function of CA IX is to catalyze the reversible conversion of carbon dioxide and water to carbonic acid, playing a role in the intra- and extracellular pH regulation of cells. It has been implicated as an intrinsic marker of hypoxia and as a prognostic marker for several types of human tumors. CA IX has also been shown to be a useful prognostic biomarker for RCC.
|CAT||Product Name||Target Species||Antibody Clone||Antibody Host||Receptor Construction||Vector Type||Targeting Cell Type||Inquiry & Datasheet|
|CAR-LC371||Anti-CA9 h(CD28-41BB-CD3ζ, iRGD) Armoured CAR, pCDCAR1||Human||Human||iRGD-scFv-CD28-41BB-CD3ζ||Lentiviral||T cell|
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE